MP
INDV icon

Mangrove Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Mangrove Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110M Sell
2,676,730
-65,704
-2% -$2.38M 7.22% 1
2026
Q1 		$83.6M Sell
2,742,434
-3,575
-0.1% -$118K 6.76% 1
2025
Q4 		$98.5M Buy
2,746,009
+3,575
+0.1% +$109K 8.03% 1
2025
Q3 		$66.1M Buy
2,742,434
+469,766
+21% +$9.83M 4.89% 2
2025
Q2 		$33.5M Buy
2,272,668
+1,559,870
+219% +$18.2M 3.6% 10
2025
Q1 		$6.79M Buy
+712,798
New +$7.49M 0.73% 34
2024
Q4 		– Sell
-1,156,010
Closed -$11.3M – 177
2024
Q3 		$11.3M Buy
+1,156,010
New +$13.5M 0.97% 31

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mangrove Partners's INDV Position: Q2 2026 in Review

Mangrove Partners reduced its Indivior Pharmaceuticals (INDV) stake by 2.4% in Q2 2026, selling an estimated $2.38M and leaving 2,676,730 shares worth $110M. The position accounts for 7.22% of the portfolio, ranked #1.

Mangrove Partners first reported a position in INDV in Q3 2024 and has held it in 7 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Mangrove Partners held 2,676,730 shares of Indivior Pharmaceuticals worth $110M as of Q2 2026.
  • Mangrove Partners sold 65,704 Indivior Pharmaceuticals shares in Q2 2026, an estimated $2.38M.
  • Indivior Pharmaceuticals made up 7.22% of Mangrove Partners's portfolio in Q2 2026, its #1 holding.
  • Mangrove Partners first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.